AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Kyverna Therapeutics, Inc.
Video analysis: KYTX
All videosNo video analysis for this stock yet. Request one from our team.
News: KYTX
Kyverna Therapeutics to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic immunotherapies at 16 weeks, with 81% mobility improvement, supporting regulatory momentum. Rolling BLA submission for miv-cel is underway, with anticipated completion in late 2026 and potential approval by mid-2027; key phase 2/3 data in myasthenia gravis expected soon.
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunology
Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement
Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. Rolling BLA submission for miv-cel in SPS is underway, targeting completion by Q4 2026, supported by positive phase 2 KYSA-8 results. The manufacturing agreement with ElevateBio secures supply for miv-cel, supporting U.S. and global commercialization and future indications.
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
EMERYVILLE, Calif., and WALTHAM, Mass.
Kyverna Therapeutics Sinks 13%: Here's Why
Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changing hands near $8.60 after opening the session at $9.81.
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation.
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026.
